ArticleCureus2025
Gastrointestinal Hemorrhage in CREST Syndrome: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Systemic scleroderma is an autoimmune disorder caused by microvascular dysfunction, excessive collagen deposition, and progressive fibrosis affecting the skin and other organs. CREST syndrome, also known as limited scleroderma, is an acronym for calcinosis, Raynaud's phenomenon, esophageal dysfunction, sclerodactyly, and telangiectasias. Among patients with systemic sclerosis (SSc), anticentromere antibodies are typically associated with the CREST syndrome variant. These antibodies are considered disease-specific and are known to correlate with the extent of disease progression. The pathogenesis of SSc is complex, with unusual presentations increasingly seen among patients. Gastrointestinal (GI) hemorrhage can be observed in CREST syndrome as an uncommon but serious complication. Endoscopic interventions are warranted in such patients to evaluate and manage bleeding. This report aims to raise awareness among physicians that CREST syndrome can present with GI hemorrhage, with skin signs such as calcinosis and sclerodactyly. In our case, H2 blockers and proton pump inhibitors were administered as part of the management plan to reduce acid-related mucosal injury and mitigate GI bleeding. Due to chronic mucosal hemorrhage, anemia was noted and corrected with parenteral iron therapy. The prognosis of CREST syndrome is relatively good when compared to the diffuse variant. Further research is needed to understand the pathophysiology of CREST syndrome, reliable biomarkers for early diagnosis, and targeted preventive treatment for this condition. Sensitizing clinicians regarding the changing disease pattern will help in prompt diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.